Is IKAP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IKAP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IKAP (€8.32) is trading below our estimate of fair value (€33.05)
Significantly Below Fair Value: IKAP is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IKAP?
Key metric: As IKAP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for IKAP. This is calculated by dividing IKAP's market cap by their current
revenue.
What is IKAP's PS Ratio?
PS Ratio
5.8x
Sales
US$220.36m
Market Cap
US$1.27b
IKAP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: IKAP is good value based on its Price-To-Sales Ratio (5.8x) compared to the European Biotechs industry average (8x).
Price to Sales Ratio vs Fair Ratio
What is IKAP's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
IKAP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
5.8x
Fair PS Ratio
3.9x
Price-To-Sales vs Fair Ratio: IKAP is expensive based on its Price-To-Sales Ratio (5.8x) compared to the estimated Fair Price-To-Sales Ratio (3.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst IKAP forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
€8.32
€10.11
+21.5%
15.1%
€12.13
€7.46
n/a
7
Nov ’25
€6.58
€8.78
+33.3%
21.5%
€11.68
€5.39
n/a
7
Oct ’25
€6.42
€8.78
+36.8%
21.5%
€11.68
€5.39
n/a
7
Sep ’25
€6.03
€8.87
+47.1%
22.9%
€12.05
€5.56
n/a
7
Aug ’25
€5.13
€8.87
+73.0%
22.9%
€12.05
€5.56
n/a
7
Jul ’25
€5.17
€9.46
+83.0%
28.6%
€13.98
€5.59
n/a
7
Jun ’25
€4.83
€9.46
+96.0%
28.6%
€13.98
€5.59
n/a
7
May ’25
€4.70
€9.77
+108.0%
23.1%
€13.86
€7.39
n/a
7
Apr ’25
€4.54
€9.77
+115.4%
23.1%
€13.86
€7.39
n/a
7
Mar ’25
€5.21
€9.77
+87.5%
23.1%
€13.86
€7.39
n/a
7
Feb ’25
€6.98
€12.06
+72.8%
14.3%
€13.69
€8.67
n/a
7
Jan ’25
€8.19
€12.32
+50.5%
14.3%
€13.99
€8.86
n/a
7
Dec ’24
€7.76
€12.32
+58.8%
14.3%
€13.99
€8.86
€8.27
7
Nov ’24
€6.65
€13.15
+97.7%
8.5%
€14.09
€11.27
€6.58
7
Oct ’24
€7.23
€13.15
+81.9%
8.5%
€14.09
€11.27
€6.42
7
Sep ’24
€8.70
€12.72
+46.2%
8.5%
€13.63
€10.90
€6.03
7
Aug ’24
€9.54
€12.60
+32.0%
9.3%
€13.78
€11.02
€5.13
7
Jul ’24
€8.77
€12.62
+43.9%
9.3%
€13.80
€11.04
€5.17
7
Jun ’24
€8.40
€12.80
+52.3%
9.3%
€14.00
€11.20
€4.83
7
May ’24
€10.08
€11.78
+16.9%
17.0%
€13.59
€8.16
€4.70
7
Apr ’24
€9.97
€12.19
+22.3%
17.0%
€14.07
€8.44
€4.54
7
Mar ’24
€8.31
€12.19
+46.7%
17.0%
€14.07
€8.44
€5.21
7
Feb ’24
€8.26
€11.51
+39.4%
24.0%
€13.75
€5.04
€6.98
8
Jan ’24
€3.43
€11.85
+245.7%
25.2%
€14.96
€5.49
€8.19
8
Dec ’23
€4.77
€11.85
+148.1%
25.2%
€14.96
€5.49
€7.76
8
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.